PhRMA Statement on Dr. Scott Gottlieb’s Nomination to Lead the U.S. Food and Drug Administration
Washington, D.C. (March 10, 2017) — Pharmaceutical Research and Manufacturers of America (PhRMA) president and CEO Stephen J. Ubl issued the following statement on President Trump’s nomination of Dr. Scott Gottlieb to lead the U.S. Food and Drug Administration (FDA):
“PhRMA congratulates Dr. Gottlieb on his nomination to serve as Commissioner of the U.S. Food and Drug Administration. His extensive experience as a physician and breadth of health care knowledge will help ensure the FDA continues to play a vital role in protecting public health and innovation in the Agency’s review and approval of new medicines for patients in need.
“We look forward to working with Dr. Gottlieb in his new role and engaging with him and the Agency as they seek to modernize the drug discovery and review process and advance competition in the biopharmaceutical market.”
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested more than half a trillion dollars in the search for new treatments and cures, including an estimated $58.8 billion in 2015 alone.
Connect with PhRMA
For information on how innovative medicines save lives, please visit: